297 related articles for article (PubMed ID: 32676572)
21. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
[TBL] [Abstract][Full Text] [Related]
22. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects.
Klein B; Treudler R; Simon JC
J Dtsch Dermatol Ges; 2022 Jan; 20(1):19-24. PubMed ID: 34962052
[TBL] [Abstract][Full Text] [Related]
23. Emerging therapies for atopic dermatitis: JAK inhibitors.
Cotter DG; Schairer D; Eichenfield L
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
[TBL] [Abstract][Full Text] [Related]
24. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
Chapman S; Kwa M; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
[TBL] [Abstract][Full Text] [Related]
25. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
Mancuso-Stewart E; Rodger J; Zirwas M
Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
[TBL] [Abstract][Full Text] [Related]
26. [Janus kinase inhibitors : Indications, efficacy, uses, what should be taken into account?].
von Martial S; Tsianakas A
Dermatologie (Heidelb); 2024 Mar; 75(3):256-267. PubMed ID: 38100043
[TBL] [Abstract][Full Text] [Related]
27. Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N; Turchin I
Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
[TBL] [Abstract][Full Text] [Related]
28. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
29. An insight into JAK-STAT signalling in dermatology.
Palanivel JA; Macbeth AE; Chetty NC; Levell NJ
Clin Exp Dermatol; 2014 Jun; 39(4):513-8. PubMed ID: 24825142
[TBL] [Abstract][Full Text] [Related]
30. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
Svoboda SA; Johnson N; Phillips M
Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
[TBL] [Abstract][Full Text] [Related]
31. [Dermatology. New uses for JAK inhibitors in dermatology: a panacea, but at what price?].
Russo G; Laffitte E; Cortes B
Rev Med Suisse; 2024 Jan; 20(859):241-246. PubMed ID: 38299954
[TBL] [Abstract][Full Text] [Related]
32. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream.
Smith P; Yao W; Shepard S; Covington M; Lee J; Lofland J; Naim A; Sheth T; Parikh B; Yeleswaram S
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371735
[TBL] [Abstract][Full Text] [Related]
33. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
34. [What's new in dermatological treatment?].
Viguier M
Ann Dermatol Venereol; 2017 Dec; 144 Suppl 4():IVS47-IVS53. PubMed ID: 29249252
[TBL] [Abstract][Full Text] [Related]
35. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
36. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
37. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
Tanaka Y; Luo Y; O'Shea JJ; Nakayamada S
Nat Rev Rheumatol; 2022 Mar; 18(3):133-145. PubMed ID: 34987201
[TBL] [Abstract][Full Text] [Related]
38. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Di Lernia V; Bardazzi F
Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
[TBL] [Abstract][Full Text] [Related]
39. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
40. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]